Featured Articles

  1. The Future Of Biologistics 11/7/2025

    Tom Wells at 4C Associates explores the future of 'biologistics,' or how the packaging, storage, and logistics for biologics might develop over the next two decades, with supply chain implications.

  2. Someone Else Can Schedule The Meeting 11/5/2025

    Leadership means knowing when to jump in and when to let someone else worry about the details, writes Hope Mueller, SVP of Corporate Development and Strategy at Currax Pharmaceuticals.

  3. M&A In GLP-1 Technology: Practical Recommendations And Best Practices 11/4/2025

    With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena.

  4. How The U.S. Can Beat China In Biotech 11/3/2025

    Lumen Bioscience's Brian Finrow breaks down China's biotech playbook and explores ways the U.S. can adapt it for its own continued success.

  5. Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads 10/31/2025

    Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.

  6. The Power Of Women Shaping The Future Of Healthcare 10/29/2025

    Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes former Melinta Therapeutics CEO Christine Ann Miller.

  7. Royalties In Hybrid Licensing Agreements: Careful Drafting Is Critical 10/27/2025

    Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, write experts at Faegre Drinker and Aurobindo Pharma USA.

  8. Are Companies Bought, Not Sold? Rethinking M&A In Life Sciences 10/24/2025

    Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write Outcome Capital's Oded Ben-Joseph, Ph.D. and Peter Meyer, Ph.D.

  9. The Moral Economics Of Precision Medicine 10/21/2025

    The most complex and expensive drugs to develop often target terrible diseases that affect only a small number of people and will never reach blockbuster status.

  10. How The New Biotech Market Is Redefining Leadership 10/20/2025

    The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and investor relations are paramount, writes Jeff Walsh, CEO of nChroma Bio.